Characterised by the immunostimulating additives, e.g. chemical adjuvants (A61K39/39)

Specific antibody to s100a4 or its fragment (versions), method of production thereof (versions), pharmaceutical composition containing said compounds, hybridoma cell line (versions), conjugate, composition, method of preventing and/or treating cancer, metastasis, angiogenesis and inflammatory diseases, method and kit for diagnosing cancer or disease associated with inflammation (versions), method of detecting s100a4, method of making individual therapy // 2615684
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Antibody to S100A4 characterized by antiangiogenic activity or its fragment in fact, preserving antiangiogenic activity of above antibody are described, wherein antibody is produced by hybridoma ECACC 10022401. Antibody contains at least area VL containing sequence SEQ ID NO: 1, and at least area VH containing sequence SEQ ID NO: 2, and identifies epitope containing sequence SEQ ID NO: 3, and it is characterized by activity profile, presented in Fig. 15. Antibody to S100A4 characterized by antiangiogenic activity or its fragment in fact preserving antiangiogenic activity of above antibody are also described, wherein antibody is produced by hybridoma selected from group comprising ECACC 11051801, ECACC 11051802 and ECACC 11051803, identifies epitope containing sequence SEQ ID NO: 24, and it is characterized by activity profile, presented in Fig. 15. Use of above antibodies in certain applications is also described.EFFECT: invention extends range of products for preventing and/or treating cancer, metastasis, angiogenesis and inflammatory diseases.36 cl, 26 dwg, 4 tbl, 16 ex

Combined therapy by afucosylated antibody for cd20 with antibody for vegf // 2615459
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biotechnology, specifically to combination therapy by afucosylated antibody for CD20 and antibody for VEGF for cancer treatment, which can be used in medicine. A afucosylated humanized B-Ly1 antibody is applied in combination with the antibody for VEGF, with a composition containing tthe said antibodies for treatment of CD20-expressing cancer, and treatment of a patient suffering from CD20-expressing cancer.EFFECT: invention can effectively inhibit the growth of CD20-expressing tumors.20 cl, 1 dwg, 2 tbl

Immunostimulating oligodeoxynucleotides // 2615457
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology. Immunostimulating methylated CpG-oligodeoxynucleotide, expression vector containing it, vaccine for preventing or controlling infectious disease in poultry, containing above oligodeoxynucleotide and/or expression vector and immunological amount of antigen component extracted from pathogenic for bird virus or microorganism, as well as application of oligodeoxynucleotide as medicinal agent and for prevention of infection in birds are disclosed.EFFECT: proposed oligodeoxynucleotide has high immunomodulatory action and can be used in veterinary as effective immunostimulating component in vaccines against infectious diseases of birds together with antigen component, extracted from virus or microorganism pathogenic for bird.29 cl, 32 dwg, 3 tbl, 24 ex

Il-1 binding proteins // 2615173
FIELD: biotechnology.SUBSTANCE: present group of invention relates to biotechnology and immunology. Bispecifical binding protein is disclosed, which contains first polypeptide chain including two variable heavy chain domains of antibody and second polypeptide chain including two variable light chain domains of antibody (DVD-Ig). Disclosed protein binds human IL-1β and IL-1α. In addition recovered nucleic acid molecule, expression vector, host cell and method of producing binding protein under invention based on their using are disclosed. Besides pharmaceutical composition, methods of reducing activity of human IL-1 and method of treating patient from inflammatory disorder are presented.EFFECT: protein under present invention has neutralizing activity with respect to human IL-1β and IL-1α and thus it can find further application in therapy of diseases associated with IL-1.15 cl, 17 tbl, 4 ex

Immunity-inducing means // 2614386
FIELD: biotechnology.SUBSTANCE: invention refers to production of means containing at least one polypeptide selected from SEQ ID NO: 4, 2, 8, 10 and 12, and/or recombinant vector(s), comprising polynucleotide(s) encoding at least one polypeptide, as the active ingredient(s), and can be used in medicine. The resulting means is used for efficient induction of T-cell immunity against malignancies expressing KATNAL1.EFFECT: invention allows to obtain antigen-presenting cells presenting the polypeptide obtained from KATNAL1, and to effectively induce cytotoxic cells against KATNAL1, which is efficient as a therapeutic agent against malignant neoplasms expressing KATNAL1.7 cl, 3 dwg, 3 ex

Stable liquid pharmaceutical preparations of fused protein tnfr: fc // 2614257
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biotechnology, namely to stable pharmaceutical compositions of fused protein TNFR: Fc. Pharmaceutical compositions and kits for their application of different physical stability TNFR:Fc are obtained by using the citrate buffer system at a concentration of 25 to 120 mM and amino acid selected from the group consisting of proline and lysine, and their pharmaceutically acceptable salts at a concentration of 15 to 100 mM as a stabilizer.EFFECT: invention allows stability of pharmaceutical compositions of etanercept for long-term storage.50 cl, 1 dwg, 17 tbl, 3 ex

Alpha-v beta-8-binding antibodies // 2614252
FIELD: pharmacy.SUBSTANCE: antibodies with high affinity for β8-subunit αvβ8 proposed. Pharmaceutical composition comprising such antibodies, and methods of their application are also described. The proposed group of inventions can be used in medicine.EFFECT: improved antibody properties.23 cl, 14 dwg, 19 ex

ethod of producing human immunoglobulin // 2614119
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Group of inventions is described, which involves method of producing human immunoglobulin and preparation of human immunoglobulin, obtained using said method. Method includes stage of dissolving of Cohn component I+II+III or Cohn component II+III in water for injections; deposition with caprylic acid or caprylate; first stage of anion-exchange chromatography, involving bringing pH of filtrate obtained at step (2), to 5.2, cleaning by anion-exchange chromatography and obtaining eluating solution; deposition of IgM, including control of conductivity of eluating solution obtained at step (3), up to 500–1,000 µS/cm by means of water and further bringing pH to 6.0–7.3,with subsequent settling for 1–2 hours, filtration and filtrate collection; second stage of anion-exchange chromatography, involving bringing pH of filtrate obtained at step (4) to 5.6, subsequent purification by anion-exchange chromatography and collection of eluating solution; production of human immunoglobulin by dialysis of eluating solution obtained at step (5), by ultrafiltration, obtaining pharmaceutical form and inactivation of viruses.EFFECT: invention extends range of methods for producing human immunoglobulin.9 cl, 2 dwg, 3 tbl, 2 ex

Conjugated protein-active agents and methods of their production // 2613906
FIELD: pharmacy.SUBSTANCE: conjugated protein active agent has an amino acid motif which can be recognized via isoprenoid transferase, wherein the active agent is covalently bound via at least one linker with izosubstrate, where the izosubstrat contains at least one isoprene unit and is a recognizable isoprenoid transferase, which is attached to a cysteine residue of the amino acid motif. The invention also relates to a composition comprising conjugates, and to methods for preparing conjugates and compositions.EFFECT: use of the conjugates for the delivery of the active agent into target cells with a high selectivity.16 cl, 27 dwg, 5 ex

Liquid composition of long-acting alpha interferon conjugate // 2613905
FIELD: medicine, pharmacy.SUBSTANCE: group of inventions refers to the field of pharmacy and medicine and relates to a liquid composition (options), in which the long-acting INF conjugateα and the immunoglobulin Fc-fragment are covalently linked by a non-peptidic polymer, and includes a stabilizer with a buffer, sugar alcohol, a nonionic surfactant and an isotonic agent; at that, it does not contain human serum albumin and other potential factors harmful for the organism. The inventive method for liquid composition production and a stabilizer are also stated.EFFECT: group of inventions provides excellent storage stability of long-acting INF conjugatesα with improved durability and stability in vivo, can be safely stored for a long period of time.17 cl, 1 dwg, 6 ex, 12 tbl
Production method of brucellar monospecific serum anti-melitensis // 2613901
FIELD: veterinary medicine.SUBSTANCE: provide the immunizations of rabbits with a single dose of B. melitensis strain. The rabbits immunization is carried out subdermally in the dewlap area with suspension of 1 ml volume, which contains:. 200 million MK inactivated culture of B. melitensis strain 16M with adjuvant MONTANIDE™ ISA 61 VG. At the 14th-16th day the trial blood collecting is conducted, and at the 21st-45th day the three-time blood collecting is carried out and at the 60th day it is dehematized. The serum is obtained and inactivated at 60-65°C during 1-1.5 hours. The cross adsorption with bacteriological weight of B. abortus 544 strain is carried out, obtained by culture growing within 70-72 hours. Centrifuge with cooling the residue during 24-26 hours, adding to the residue the physiological solution for obtaining the bacterial weight in the amount of 3.5-3.7×109 pfu per 10 ml of serum. Further incubate at 37°C for 2 hours and restore the serum by centrifugation with further preserving and packaging.EFFECT: utilisation of this method allows the use the inactivated Brucella culture to produce a monospecific serum, and take blood from each of the rabbits for at least four-times, increasing the amount of the resulting serum.2 ex, 8 tbl

Antibody for blys // 2613422
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biochemistry. The antibody for BLyS is stated. The invention also relates to the DNA molecule encoding the said antibody, the expression vector and the host cell to produce the said antibody. It is also proposed to use BLyS antibodies in a pharmaceutical composition and in the method for prevention and/or treatment of diseases caused by excessive proliferation of B-cells, such as systemic lupus erythematosus. The invention allows binding to BLyS with high affinity and inhibition of binding to its receptor with high BR3 specificity.EFFECT: invention adds a new BLyS antibody concept to biochemistry with a proposal to use the antibody for prevention and/or treatment of diseases caused by excessive proliferation of B-cells.15 cl, 10 dwg, 4 tbl, 10 ex

ethod for preparing composition of immunoglobulins // 2612899
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology. Disclosed is method for producing composition containing IgM immunoglobulins from plasma fractions. Also described is antibody preparation produced by such method, and use of this preparation for therapy of patients or preparing medicine for treating immunological disorders and bacterial infections.EFFECT: method involves providing plasma fraction in form of solution containing immunoglobulins, mixing solution with octanoic acid, treatment of mixed solution in vibromixer for deposition of contaminating proteins, and separation of deposited proteins from solution to obtain composition containing IgM from immunoglobulins.30 cl, 1 dwg, 11 tbl, 9 ex
ethod for treatment of locally spread unresectable esophageal cancer // 2612090
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to oncology, and can be applied for treatment of locally spread unresectable esophageal cancer. For this purpose in conditions of procedure room after processing chest skin with antiseptic solution patients receive intradermally by 0.3 ml of autologous dendritic-cell vaccine, two injections from each side of chest approximately between III and IV, IV and V ribs. Dose constitutes 5,000,000 dendritic cells. 2 weeks after introduction of first vaccine second dendritic-cell vaccine is introduced in the same dose. 2 weeks after introduction of second vaccine third dendritic-cell vaccine is introduced in total dose 10,000,000 dendritic cells. 2 weeks after third introduction of vaccine fourth dendritic-cell vaccine is introduced in total dose 10,000,000 dendritic cells. During the entire course of vaccine therapy patients receive 30,000,000 cells.EFFECT: invention makes it possible to increase duration and to improve quality of life in patients with locally spread unresectable esophageal cancer.1 ex

Pharmaceutical composition for cancer treatment and/or prevention // 2611197
FIELD: medicine, pharmacy.SUBSTANCE: invention relates to biochemistry, namely to an antibody or fragment thereof, wherein the antibody or fragment thereof specifically binds to CAPRIN-1 protein, DNA, its encoder, as well as to a conjugate of the said antibody or fragment thereof with an antitumor agent. The invention also relates to pharmaceutical composition and pharmaceutical combination for cancer treatment or prevention, in which CAPRIN-1 is expressed on the malignant cell surface, as well as to a method for cancer treatment or prevention, in which CAPRIN-1 is expressed on the malignant cell surface using the above antibody or fragment thereof.EFFECT: invention enables efficient cancer treatment or prevention, in which CAPRIN-1 is expressed on the malignant cell surface.8 cl, 7 ex

Antigen-binding molecules, which bind egfr, vectors coding them and use thereof // 2610688
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology and immunology. Invention discloses isolated polynucleotides coding variable regions of light and heavy chains of antibody to human EGFR; anti-EGFR antibody and antibody fragment; as well as vector, host cell and method of producing anti-EGFR antibody or its fragment. There are disclosed: composition containing anti-EGFR antibody or its fragment, use thereof, as well as use of antibody and its fragment for treating disorders characterized by EGFR overexpression. Besides, method of detecting presence of EGFR in sample using disclosed antibodies is described.EFFECT: present invention can find further application in treating EGFR-mediated diseases.70 cl, 29 dwg, 38 tbl, 5 ex

Antibody blocking agr2, and use thereof // 2610665
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and immunology. AGR2 blocking monoclonal antibody is described and in particular humanized monoclonal antibody for AGR2 blocking. Invention also describes pharmaceutical composition containing antibody, production method thereof and application of antibody for blocking tumor growth and metastasis.EFFECT: disclosed group of inventions can be used in medicine.20 cl, 28 dwg, 11 ex

Antibodies to folic acid receptor 1, their immunoconjugates and application // 2610663
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and immunology. Humanized antibody and its antigen-binding fragment are disclosed, specifically binding to human folic acid receptor 1 (FOLR1) and characterized by amino acid sequences of sections determining complementarity with antigen (CDR). Method of producing humanized antibodies under invention; immunoconjugates with cytotoxic agent; pharmaceutical composition; diagnostic composition; kits; methods of inhibiting tumor growth and method of treating cancer are also disclosed. Isolated polynucleotides coding variable domains of disclosed antibodies; vectors containing them and host cells are also disclosed.EFFECT: antibody under invention is humanized form of mouse antibody Mov19 and it can find further application in therapy of diseases characterized by high expression of FOLR1.69 cl, 19 dwg, 4 tbl, 19 ex

Cd37 binding molecules and immunoconjugates // 2610662
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and immunology. Antibodies are described, which specifically bind to human CD37 and macaque CD37. Immunoconjugate, consisting of antibody and cytotoxic agent, and application of antibody or immunoconjugate for treating oncological disease are also described.EFFECT: disclosed group of inventions can be used in medicine.25 cl, 32 dwg, 11 tbl, 17 ex
ethod of treating pathological syndrome and drug of central and peripheral action for treating pathological syndrome // 2610438
FIELD: medicine.SUBSTANCE: invention relates to medicine and represents method of treating obesity, nicotine addiction and reduction of alarm, while smoking cessation by administering drug central and peripheral action in body, which is based on activated potentiated form of antibodies. Disclosed method is characterized by that drug contains activated potentiated form of antibodies to human cannabinoid receptor in form of activated potentiated aqueous or aqueous-alcoholic solution, obtained during successive multiple dilution of matrix solution in water or aqueous-alcohol solvent and intermediate external mechanical action.EFFECT: higher efficiency of treating obesity, nicotine addiction and reduction of alarm, while smoking cessation.17 cl, 12 tbl, 7 ex

Pharmaceutical composition for treating and/or preventing malignant growth // 2610428
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, namely to antibody or its fragment, which possess immune responsiveness in relation to protein CAPRIN-1. Invention also discloses antibody, which specifically binds to CAPRIN-1, pharmaceutical composition containing said antibody or its fragment or conjugate for treating or preventing malignant tumors, associated with CAPRIN-1, DNA, coding said antibody. Method of treating or preventing malignant tumors, associated with CAPRIN-1, using disclosed antibody is proposed.EFFECT: invention enables specific binding to CAPRIN-1, which enables effective treatment of malignant tumor associated with expression of CAPRIN-1.8 cl, 8 ex

Composition containing antibody // 2609658
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Described is a pharmaceutical composition for treating angiogenic diseases, comprising an antibody, which binds with VEGF, in an arginine acetate buffer, pH 4.5–6.0, and a surfactant, where antibody is bevacizumab.EFFECT: invention enables to obtain a stable aqueous pharmaceutical composition containing a therapeutically effective amount of an antibody.70 cl, 4 dwg, 8 tbl

Anti-cd40-antibodies and methods of application // 2609647
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biochemistry. An isolated antibody or antigen-binding fragment that is bound to human CD40 and acts as agonists of CD40 is described. An isolated polynucleotide encoding an isolated antibody or antigen-binding fragment thereof, an expression vector containing an isolated polynucleotide isolated host cell to produce an antibody or antigen-binding fragment thereof are described. A composition for treatment or alleviation of a disease or disorder associated with CD40, comprising a physiologically acceptable carrier and a therapeutically effective amount of the isolated antibody or antigen-binding fragment thereof is presented. Methods for treatment or alleviation of symptoms for patients having cancer, reduction of symptoms for patients having autoimmune diseases, alleviation of symptoms for patients having inflammatory diseases, including composition injection are presented.EFFECT: invention increases the variety of CD40 antagonists.29 cl, 18 dwg, 1 tbl, 3 ex

High affinity and aggregationally stable antibodies based on vl variable domains and vhh derivative // 2609627
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biochemistry. A humanized IgG type monoclonal antibody that binds to human 17A interleukin is proposed. The antibody contains variable domains as a combination of VHH derivative with a light chain VL variable domain. The said VHH derivative contains amino acid substitutions at positions 44 and 45 (according to Kabat numbering). The invention also refers to DNA encoding the antibody, expression vector, cell line and a method for production of the said antibody. Furthermore, a pharmaceutical composition for treatment of IL-17A-mediated disease or disorder, comprising the antibody is proposed.EFFECT: invention allows to obtain antibodies with high affinity and enhanced aggregation stability.15 cl, 17 dwg, 6 tbl, 19 ex

Humanised antibodies to liv-1 and use thereof for treating cancer // 2608646
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, particularly to humanised antibody, which specifically binds to LIV-1, as well as a nucleic acid coding mature variable heavy chain region and to nucleic acid coding mature variable light chain region of said antibody. Also disclosed is a conjugate of said humanised antibody with cytotoxic or cytostatic agent for treatment or preventive treatment of cancer, associated with expression of LIV-1. Invention also relates to a method of treatment or preventive treatment of a patient, having cancer or at risk of cancer associated with expression of LIV-1, as well as to a pharmaceutical composition for treatment or preventive treatment of cancer associated with expression of LIV-1.EFFECT: invention provides effective treatment or preventive treatment of cancer associated with expression of LIV-1.21 cl, 28 dwg, 8 tbl, 3 ex

Anti c-met receptor protein antibodies // 2608644
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Described is an antibody or its antigen-binding fragment which specifically binds to human c-Met protein. Also described is an isolated polynucleotide coding said antibody, an expression vector containing said polynucleotide, a host cell containing said vector. Disclosed is a method of producing a recombinant antibody by culturing described host cell. Disclosed is a pharmaceutical composition for treating cancer and an immunoconjugate containing described antibody. Disclosed is a method of treating cancer involving administering described antibody.EFFECT: invention widens range of agents for treating cancer.15 cl, 25 dwg, 16 tbl, 26 ex

Fcγriib-specific fc-antibody // 2608504
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Described is a polypeptide, comprising a Fc-domain of an antibody with at least one amino acid modification, which has high activity of binding with FcγRIIb in comparison with initial polypeptide, where value [value KD polypeptide containing Fc-domain of antibody against FcγRIIa (type R)]/[value KD polypeptide containing Fc-domain of antibody against FcγRIIb] is equal to or greater than 1.2, where value [value KD for higher activity of binding polypeptide containing Fc-domain of antibody against FcγRIIa (type R) and FcγRIIa (type H)]/[value KD for higher activity of binding initial polypeptide on FcγRIIa (type R) and FcγRIIa (type H)] is 0.7 or more, and where amino acid modification is a replacement of Pro in position 238 (EU numeration) with Asp or replacement of Leu in position 328 (EU numeration) with Glu. Described are methods of producing said polypeptide and use thereof.EFFECT: invention widens range of therapeutic and preventive agents.20 cl, 16 dwg, 12 tbl, 9 ex

Serotonin 5-ht3 receptor antagonists for application in treatment of lesional vestibular disorders // 2608458
FIELD: medicine.SUBSTANCE: invention relates to medicine and consists in application of serotonin 5-HT3 receptor antagonist for treatment of damages during vestibular disorders, wherein, mentioned damage is characterized by damage of internal ear cells and/or vestibular nerve cells, wherein, serotonin 5-HT3 receptor antagonist is selected from a group comprising ondansetron, palonosetron, tropisetron, lerisetron, alosetron, granisetron, dolasetron, bernesetron, ramosetron, azasetron, itasetron, zakoprid and cilansetron; and mentioned serotonin 5-HT3 receptor antagonist is introduced to the patient, at least during 5 days.EFFECT: treatment of damages during vestibular disorders.4 cl, 4 ex, 6 dwg
ethod of treating patients with x-linked agammaglobulinemia // 2608128
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to clinical immunology, and can be used for treating patients with X-linked agammaglobulinemia (X-AGG). For this patient gets replacement therapy of intravenous immunoglobulins. In addition from first day of treatment and every next six months after its start for first 10 days of each half of year patient gets 2 times day, in morning and evening, every 12 h oral administration of Polyoxidonium in dose of 12 mg.EFFECT: invention provides reduced number of infectious diseases in said category of patients due to recovery of adaptive capability of phagocytes.1 cl
Combination of ozogamicin inotuzumab and torizel for treating cancer // 2607594
FIELD: medicine.SUBSTANCE: invention relates to therapeutic method of treating cancer, which is non-Hodgkin’s lymphoma; method involves stage of introducing simultaneously or successively effective number of ozogamicin inotuzumab (SMS-544) in dose of 0.4 mg/m2 up to 1.8 mg/m2 every 4 weeks throughout 6 cycles and temsirolimus in dose of 5 to 175 mg/week during disease progression.EFFECT: invention provides low toxicity, associated with treatment using ozogamicin inotuzumab or temsirolimus.7 cl, 8 ex, 11 tbl

New antibody to c-met // 2607377
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, namely to monoclonal antibody, which is capable of inhibiting dimerization of c-Met. Composition for preventing and treating cancer, associated with c-Met, containing said antibody is also disclosed. Application of said antibody and composition is disclosed for preparing therapeutic agent against cancer, associated with c-Met.EFFECT: invention is capable of total inhibiting dimerization of c-Met, which enables effective treatment of cancer, characterized by ligand-independent c-Met activation.19 cl, 39 dwg, 4 tbl, 20 ex

Pharmaceutical composition for treatment and/or prevention of cancer // 2607366
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, particularly to an antibody which specifically binds with CAPRIN-1 protein and having immunological reactivity with respect to a partial polypeptide of CAPRIN-1 protein, wherein said antibody has cytotoxic activity against a cancer cell expressing CAPRIN-1 protein, as well as a medicinal agent containing same. Invention also relates to a method of treating or preventing CAPRIN-1 expressing cancer using said antibody or composition.EFFECT: invention provides effective treatment or prevention of CAPRIN-1 expressing cancer.17 cl, 3 dwg, 6 ex

ethods and compositions for treating lupus // 2607022
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Disclosed is a method of increasing FoxP3+ regulatory T cells in a patient with lupus, comprising administering to patient a therapeutically effective amount of an anti-CD52 antibody. Also disclosed is use of monoclonal anti-CD52 antibody for preparing a drug for increasing number of FoxP3+ regulatory T-cells, as well as a kit comprising said anti-CD52 antibody and a second agent stimulating FoxP3+ regulatory T-cells.EFFECT: invention enables to relieve lupus symptoms a patient.29 cl, 25 dwg, 1 tbl, 8 ex
Enhanced immune response in bovine species // 2606855
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutics and concerns an immunomodulator composition for treating bovine respiratory disease in cattle caused by Mannheimia haemolytica, which comprises a cationic liposome delivery vehicle and nucleic acid molecule, where nucleic acid molecule is a bacterially-derived non-coding DNA plasmid vector, produced in E.coli, containing 4242 base-pairs without a gene insert.EFFECT: invention provides a eliciting systemic, non-specific and antigen-specific immune responses in animals for protection against infectious respiratory disease.11 cl, 6 ex, 6 tbl, 27 dwg

ethod of modification of polypeptide for purification of polypeptide multimers // 2606264
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and represents method of polypeptide multimer production, which includes first polypeptide with antigen-binding activity and second polypeptide with antigen-binding activity or in addition to first and second polypeptides multimer includes one or two third polypeptides with antigen-binding activity or in addition to first, second and third polypeptides multimer includes fourth polypeptide with antigen-binding activity; and method involves following steps: (a) expression of DNA, which codes first polypeptide with antigen-binding activity, and of DNA, which codes second polypeptide with antigen-binding activity, or expression of DNA, which codes first, second and third polypeptides with antigen-binding activity, or expression of DNA, which codes first, second, third and fourth polypeptides with antigen-binding activity; and (b) assembling of expression product of stage (a) using affinity chromatography with protein A.EFFECT: invention enables to obtain multimers with antigen-binding activity of high purity as a result of only purification step, based on protein A.44 cl, 18 dwg, 18 tbl, 12 ex

Aldehyde marked immunoglobulin polypeptides and methods of their application // 2606016
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology, namely to producing aldehyde marked antibody for conjugation with drug of interest, and can be used in medicine. Obtained antibody can be modified with formylglycine-forming enzyme to make 2-formylglycine modified (FGly) antibody, which can be covalently and site specificly is conjugated with target fragment.EFFECT: invention enables to obtain conjugate, capable of directed delivery in antigen expressing body tissues.60 cl, 33 dwg, 3 ex

Therapeutic dll4-binding proteins // 2605928
FIELD: medicine.SUBSTANCE: present invention relates to immunology. Antibody and its antigen-binding fragment specifically binding human delta-like ligand 4 (DLL4) are presented, characterized by sequences determining sections complementarity (CDR). Besides, there are disclosed: isolated antibody coding nucleic acid under the invention or its antigen-binding fragment; expression vector and host cell; as well as, pharmaceutical composition and application of antibody or antigen-binding fragment according to the invention in preparing a drug for reducing human DLL4 activity in an individual human.EFFECT: present invention can find further application in therapy of diseases associated with Notch signaling.29 cl, 30 tbl, 13 ex

Antibodies against g-csfr and use thereof // 2605595
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Versions of antibody binding human granulocyte colony-stimulating factor receptor (hG-CSFR) are disclosed. Invention also discloses composition and method of treating G-CSF-mediated state in subject.EFFECT: invention enables to bind hG-CSFR with high affinity and neutralize transmission of G-CSF signals.13 cl, 4 dwg, 3 tbl, 6 ex

Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use // 2605390
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and concerns a bispecific antibodies that specifically bind a T-cell activating antigen and a tumor antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain, so that the constant region of the heavy chain consists of one or more CH1 domains. Group of inventions also relates to a host cell, comprising vectors comprising nucleic acid molecules, encoding the light chains and heavy chains of the bispecific antibody; application of bispecific antibody in preparing a drug for treating cancer.EFFECT: group of inventions provides inducing T cell-mediated apoptosis of target cells.19 cl, 9 ex, 23 dwg, 1 tbl

Anti-il-17f antibodies and methods for use thereof // 2605318
FIELD: medicine; immunology.SUBSTANCE: preset invention relates to immunology. Disclosed is an isolated anti-IL-17F antibody and an antigen-binding fragment thereof, which are characterised by CDR sequences for heavy and light chains. A method of producing an antibody according invention and an antigen-binding fragment thereof is disclosed. Furthermore, based on use of antibody according to present invention and antigen-binding fragment thereof, a pharmaceutical composition is provided, as well as a method of alleviating a symptom of an autoimmune disease or an inflammatory disorder and a method of alleviating a symptom of the arthritis condition in a subject.EFFECT: present invention can be further used in treatment of diseases associated with elevated levels of IL-17F.23 cl, 2 dwg, 4 tbl, 7 ex

Humanized antibody to cd52 // 2605307
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Antibody to human CD52 is disclosed. Antibody is used for treatment or diagnostics of diseases associated with CD52+ cells, such as CLL and other leukemias, autoimmune diseases, organ transplant rejection, reaction “graft-versus-host” disease.EFFECT: invention enables to bind CD52.20 cl, 14 dwg, 2 tbl, 11 ex

Biomarkers based on tumor tissue for combined therapy with bevacizumab // 2605282
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine, namely to oncology, and is intended for increasing survival without progression of disease in patient suffering colon or rectum metastatic cancer. For implementation of method, tissue samples are obtained from above patient, VEGFA and/or CD31 expression is determined, and Bevacizumab combined with chemotherapy schedule is administered to patient. Patient therein has higher level of VEGFA and/or CD31 relative to reference levels defined in patients with colon or rectum metastatic cancer. Said chemotherapy schedule represents oxalic platinum chemotherapy schedule. Also, in vitro method is provided for detecting patients responding or sensitive to adding Bevacizumab for treatment to chemotherapy schedule.EFFECT: application of invention group allows to increase survival rate of patients with colon or rectum metastatic cancer without progression of disease.15 cl, 8 dwg, 4 tbl, 1 ex

Versions of humanized immunomodulatory monoclonal antibodies // 2604814
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Humanized antibody BAT-1 or its antigen-binding fragment are described, which have anti-tumor and immunostimulating activity, containing variable light chain domain, as shown in SEQ ID NO:1, where Phe97 is substituted by Ala, and variable heavy chain domain, as shown in SEQ ID NO:5, where Trp107 is substituted by Ala. Invention also describes polynucleotide coding described antibody, expression vector and host cell containing said polynucleotide. Use of above antibody for treating malignant tumor and immunodeficiency disorders in individual is described.EFFECT: invention extends range of products for treating malignant tumors and immune disorders.17 cl, 1 dwg, 2 tbl, 7 ex

ethod for preparing antibodies having improved properties // 2604811
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and represents a Fc-containing polypeptide containing amino acid sequence SEQ ID NO: 18, where SEQ ID NO: 18 comprises mutations at amino acid positions 243 and 264 of Fc region, where Fc-containing polypeptide represents an antibody or antibody fragment containing sialylated N-glycans, and where mutation in position 243 represents F243A and mutation in position 264 represents V264A, where numbering is made according to EU index as in Kabat, where Fc-containing polypeptide has low binding with FcγRI, FcγRIIa, FcγRIIb and/or FcγRIIIa compared to parent Fc-containing polypeptide. Invention also relates to a method of producing said Fc-containing polypeptide in a host cell, as well as to a method of treating an inflammatory condition in an individual in need thereof, involving administering a therapeutically effective amount of said Fc-containing polypeptide.EFFECT: invention enables to obtain Fc-containing polypeptide having reduced binding with FcγRI, FcγRIIa, FcγRIIb and/or FcγRIIIa compared with parent Fc-containing polypeptide.13 cl, 22 dwg, 14 tbl, 24 ex

Design of stable heterodimeric antibody with mutations in fc domain // 2604490
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Carcasses are described, which contain heavy chains, being asymmetric in different domains (for example, CH2 and CH3), to achieve selectivity between different Fc receptors involved in modulation of effector function, higher selectivity than selectivity, achieved when using natural homodimeric (symmetrical) Fc molecules, and increased stability and purity of produced alternative Fc homodimers as a result.EFFECT: these new molecules contain complexes of heterogeneous components formed in order to change the behavior of natural antibodies and their use in medicinal agents.80 cl, 38 dwg, 12 tbl, 8 ex

Antibodies to cd70 // 2604196
FIELD: medicine.SUBSTANCE: present invention relates to immunology. Antibody and its antigen-binding fragment are proposed, binding to human CD70, which are characterized by amino acid sequences of CDR variable domains of heavy and light chains. Extracted polynucleotide, coding antibody or antigen-binding fragment according to invention, as well as expression vector, host cell, cell-free expression system and method of producing antibody or its antigen-binding fragment, according to the invention are disclosed. Pharmaceutical composition, method of tumor cell growth inhibiting and method of exhaustion of CD70-expressing cells in patient are also disclosed.EFFECT: present invention can find further application in therapy and diagnosis of diseases, namely cancer and autoimmune diseases characterized by CD70 expression.27 cl, 24 dwg, 29 tbl, 21 ex

Using anti-amyloid beta antibody in ophthalmic diseases // 2604181
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Disclosed is a composition for preventing, treating or diagnosing an eye disease associated with amyloid-beta related pathological abnormalities or changes in visual system tissues. Composition contains an effective amount of amyloid beta-binding antibody. Also disclosed is a method of protecting visual retinal ganglion cells from amyloid-beta induced neuronal degradation, as well as methods of diagnosing, preventing, treating, facilitating development, monitoring minimal residual manifestations, predicting sensitivity of a subject to treatment of eye diseases associated with amyloid-beta related pathological abnormalities or changes. Said methods involve administering a composition containing an antibody to amyloid-beta to a subject.EFFECT: invention can be used in treating ophthalmic diseases.68 cl, 20 dwg, 14 tbl, 3 ex

Immunoglobulins k human cd52 // 2603743
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Disclosed are versions of a monoclonal antibody against human CD52. Invention also discloses isolated nucleic acids and recombinant expression vectors, coding an antibody or a light chain or a heavy chain of antibody against human CD52, host cells, as well as method of producing said antibody. Antibodies against human CD52 can be used for therapeutic purposes for treating, for example, an autoimmune disease, cancer, non-Hodgkin lymphoma, multiple sclerosis and chronic lymphocytic leukaemia.EFFECT: invention increases antibody-dependent cell-mediated cytotoxicity of antibodies against human CD52.45 cl, 246 dwg, 29 tbl, 70 ex

Pharmaceutical composition for treatment and/or prevention of cancer // 2603742
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, particularly to an antibody which specifically binds to CAPRIN-1 protein. Invention also discloses a monoclonal antibody having immunological reactivity to CAPRIN-1 protein, antibodies which specifically bind with CAPRIN-1 protein, a medicinal agent containing said antibodies for treating or preventing CAPRIN-1 expressing cancer. Disclosed are methods of treating or preventing CAPRIN-1 expressing cancer, using disclosed antibody and said medicinal agent.EFFECT: invention is capable of specifically binding to CAPRIN-1, which provides effective treatment of diseases associated with expression of CAPRIN-1 protein.16 cl, 2 dwg, 7 ex

Human antibodies to pcsk9 for use in methods of treating particular groups of subjects // 2603481
FIELD: medicine.SUBSTANCE: present group of inventions refers to medicine, namely to treating diseases or conditions, in which proprotein convertase subtilisin/kexin type 9 (hPCSK9) expression or activity is involved. For this purpose it is performed administration of hPCSK9-specific antibodies or antigen-binding fragments thereof. At that, the pharmaceutical composition contains a fixed doses of the above antibody of 75, 150 or 300 mg. Administration of the composition is performed every two or four weeks.EFFECT: said administration schedule of the composition provides the effective treatment of said diseases or pathological conditions with minimal side effects.25 cl, 6 dwg, 4 ex
 
2551080.
Up!